Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
批准号:
8068821
负责人:
SCOTT W HIEBERT
金额:
$37.52万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-05-01 至 2015-02-28
关键词:
AddressAdultAffectApoptosisCell CycleCell Cycle RegulationChromatinChromatin StructureComplexCoupledDNADNA DamageDNA Double Strand BreakDNA RepairDNA damage checkpointDNA replication forkDataDefectDevelopmentEmbryoEngineeringEnzymesEtiologyExcisionFatty acid glycerol estersFibroblastsGene ExpressionGene SilencingGenesGenetic RecombinationGenetic TranscriptionGenome StabilityGenomic InstabilityGerm LinesHDAC3 geneHeterochromatinHistone AcetylationHistone Deacetylase InhibitorHistonesHormonesImmune responseIn VitroKnowledgeLeadLinkLiverLiver diseasesMalignant NeoplasmsMediatingMusNonhomologous DNA End JoiningNormal CellNormal tissue morphologyNuclearNuclear Hormone ReceptorsPathway interactionsPatternPhenotypePhysiologicalPreventionPrimary carcinoma of the liver cellsProteinsRegulationRequest for ApplicationsRoleS PhaseT-Cell LymphomaTestingTherapeuticTherapeutic InterventionTimeTranslatingVorinostatcancer cellcancer therapygene repressionhistone deacetylase 3histone modificationhomologous recombinationhuman NCOR1 proteinin vivokillingsnon-alcoholic fatty liverpublic health relevancereceptor functionrepairedresponsetherapeutic targettumortumor specificity
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Histone deacetylases regulate chromatin structure, transcription, replication, and DNA repair/recombination. Because of these key roles in cell cycle control, HDACs have become an important target for therapeutic intervention in a variety of tumors and the first Histone Deacetylase Inhibitor (HDI) has received FDA approval. Histone deacetylase 3 (Hdac3) is a key regulator of chromatin structure and gene expression and our preliminary data suggests that it may be a central target of HDIs. Because of the multi-faceted action of histone deacetylases, it has been difficult to pin down how inhibiting these enzymes acts to kill cancer cells while sparing surrounding normal tissues. Therefore, we set out to understand the action of Hdac3 by engineering mice containing a "floxed" Hdac3. Deletion of Hdac3 in the germ line caused early embryonic lethality. Moreover, Hdac3 deletion was even lethal to murine embryonic fibroblasts in vitro. Although we approached this analysis with a "transcription bias", gene expression array analysis failed to identify the induction of a gene expression pattern that might explain this apoptosis. By contrast, careful analysis of the cell cycle indicated that apoptosis required S phase progression and that S phase was slowed. Surprisingly, the S phase DNA damage checkpoint was activated in the absence of Hdac3. This observation, coupled with data linking Hdac3 to DNA repair, led us to the discovery that loss of Hdac3 caused DNA damage that was most likely due to inefficient repair of the DNA double strand breaks that occur at stalled DNA replication forks. We have now begun to translate this information to the in vivo requirements for Hdac3 in adult mice. Removal of Hdac3 in the mouse liver caused a phenotype similar to non-alcoholic fatty liver disease, which was likely due to de- regulated nuclear hormone receptor functions. Most importantly, consistent with defects in DNA repair and genomic instability, the liver-specific deletion of Hdac3 caused a 100% penetrant hepatocellular carcinoma with a mean time to HCC of 10.2 months. We hypothesize that Hdac3 is required for efficient DNA repair and that loss of Hdac3 causes genomic instability that leads to cancer development, but that we can take advantage of these defects in DNA repair to treat cancer. This proposal will further define the mechanisms by which inactivation of Hdac3 affects DNA repair, regulates chromatin structure, and causes hepatocellular carcinoma.
PUBLIC HEALTH RELEVANCE: Histone deacetylase 3 (Hdac3) is a key factor controlling the expression of genes, which may be a therapeutic target for cancer therapy. This application addresses the role of this key gene in the cause, prevention, and treatment of hepatocellular carcinoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
-
批准号:10445091
-
项目类别:
-
资助金额:$42.29万
-
财政年份:2021
-
负责人:SCOTT W HIEBERT
-
依托单位:
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
-
批准号:10298288
-
项目类别:
-
资助金额:$45.72万
-
财政年份:2021
-
负责人:SCOTT W HIEBERT
-
依托单位:
Role of PRC1 in RUNX1-ETO-mediated transcriptional control
-
批准号:10652591
-
项目类别:
-
资助金额:$42.26万
-
财政年份:2021
-
负责人:SCOTT W HIEBERT
-
依托单位:
Regulation of transcription and tumor suppression by MTG family members
-
批准号:9265416
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2014
-
负责人:SCOTT W HIEBERT
-
依托单位:
Regulation of transcription and tumor suppression by MTG family members
-
批准号:8696545
-
项目类别:
-
资助金额:$36.36万
-
财政年份:2014
-
负责人:SCOTT W HIEBERT
-
依托单位:
Regulation of transcription and tumor suppression by MTG family members
-
批准号:9055662
-
项目类别:
-
资助金额:$36.4万
-
财政年份:2014
-
负责人:SCOTT W HIEBERT
-
依托单位:
FASEB SRC on HDACs, Sirtuins and Reversible Acetylation in Signaling and Disease
-
批准号:8595760
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2013
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8607465
-
项目类别:
-
资助金额:$39.1万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
-
批准号:9924498
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8431792
-
项目类别:
-
资助金额:$37.9万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8230922
-
项目类别:
-
资助金额:$40.45万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
-
批准号:10162514
-
项目类别:
-
资助金额:$39.06万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Hdac3 as a therapeutic target in BCL6-dependent lymphoma
-
批准号:8791883
-
项目类别:
-
资助金额:$40.31万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Establishing that Hdac3 is a therapeutic target in a subset of B cell Lymphoma
-
批准号:10406170
-
项目类别:
-
资助金额:$38.28万
-
财政年份:2012
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8447369
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:7889851
-
项目类别:
-
资助金额:$38.59万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8217259
-
项目类别:
-
资助金额:$37.47万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Inactivation of Hdac3 in the cause, prevention, and treatment of HCC
-
批准号:8615915
-
项目类别:
-
资助金额:$36.1万
-
财政年份:2010
-
负责人:SCOTT W HIEBERT
-
依托单位:
Function of MTG16/ETO2 in acute leukemia
-
批准号:7798492
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2007
-
负责人:SCOTT W HIEBERT
-
依托单位:
Function of MTG16/ETO2 in acute leukemia
-
批准号:7393198
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2007
-
负责人:SCOTT W HIEBERT
-
依托单位:
海外基金